Consisting of trillions of microbes with highly variable composition among individuals, the human gut microbiome provokes subject-specific response to drugs such as cancer drugs leading to non-effective treatments and toxic side effects. Similarly, close associations have been identified between the gut microbiome and various diseases such as inflammatory bowel disease and coeliac disease, leading to an increasing interest to modulate the microbiota to prevent/treat diseases. Nonetheless, there is no fast, cost-effective, and reliable means for predicting the individual-specific outcome of human-drug interactions.

To address this challenge, Nexilico, Inc. is offering a first-of-its-kind predictive solution at the intersection of precision medicine and microbiome research with the ultimate goal of predicting the individual-specific response of the human gut microbiome to therapeutics and leverage that information to improve drug development and personalize therapeutics.